NK cell neoplasias

Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home Genes Leukemias Solid Tumours Cancer-Prone Deep Insight Case Reports Journals Portal Teaching

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

NK cell neoplasias

Clinics and Pathology

Disease Neoplasms of natural killer (NK) cells are rare, and have not been well characterized until the past decade. In the new WHO classification of hematolymphoid tumors, three categories of NK cell neoplasms are recognized:
- extranodal NK/T cell lymphoma ,
- aggressive NK cell leukemia, and
- blastic NK cell lymphoma.
Blastic NK cell lymphoma is morphologically and immunologically different from the first two categories, lacks EBV association, and there is little compelling evidence that it truly represents an NK cell neoplasm. In fact, recent studies suggest that this may be a neoplasm of probable precursor dendritic cells related to plasmacytoid monocytes (plasmacytoid dendritic cells). Since its lineage is still uncertain, this entity will not be discussed.

Phenotype / cell stem origin NK cell represents a distinctive lineage of lymphocyte that is closely related to T cell. It shows many immunophenotypic and functional similarities with cytotoxic T lymphocyte, but differs in the lack of expression of surface CD3 molecule and T-cell receptor, and the absence of rearranged T-cell receptor genes. It characteristically expresses CD56 (neuronal cell adhesion molecule, N-CAM), which is also expressed in some cytotoxic T lymphocytes. NK cells can lyse target cells without prior sensitization (spontaneous antibody-independent MHC-unrestricted cytotoxicity) via the NK receptors.

Etiology The exact etiology is unknown, but a very strong association with Epstein Barr virus (EBV) has been demonstrated.

Epidemiology NK cell neoplasms show a strong geographic differences in their prevalence. They are more common in Asia, Mexico, and South America, but are very rare in the Western populations.

Clinics They occur predominantly in the nose/nasopharynx, but sometimes in extranasal sites (most commonly skin), in middle-aged to elderly patients. Systemic involvement is uncommon at diagnosis but rarely, they may present initially in a leukemic form. The most common presenting symptoms are nasal obstruction, nasal discharge and epistaxis. The full-blown midfacial destructive and ulcerative lesions (hence the name midline granuloma) are much less commonly seen nowadays. Patients with aggressive NK cell leukemia present with high swinging fever, systemic symptoms and hepatosplenomegaly; they are usually extremely ill, with deranged liver function and coagulation profile.

Cytology The neoplastic NK cells are often heterogeneous in appearance but some (particularly the circulating leukemic cells) may resemble large-sized normal large granular lymphocytes with ample amount of pale or lightly blue cytoplasm that contains fine or coarse azurophilic granules.

Pathology The malignant infiltrate is diffuse, often with a prominent angiocentric and angiodestructive component. Coagulative necrosis and apoptosis are common. The cytological spectrum is variable, ranging from small, medium-sized, large or anaplastic cells, to a mixture of these cells. The cells often have irregularly folded nuclei and granular chromatin. In Giemsa-stained cytologic preparations, azurophilic granules are often detected in the cytoplasm. Reactive histiocytes with haemophagocytosis are sometimes found in the bone marrow, particularly for the leukemic form. NK cell neoplasms are characterised by an immunophenotype of CD2+, surface CD3-, cytoplasmic CD3e+, CD56+ and T cell receptor (TCR)-, lack of TCR gene rearrangement, and strong association with EBV.

Treatment The disease is often resistant to chemotherapy. For extranodal NK/T cell lymphoma, the best results are obtained by radiotherapy with or without aggressive chemotherapy/stem cell rescue. Plasma or serum EBV DNA and tissue p73 gene hypermethylation assay can be used for monitoring of disease status or detection of minimal residual disease. Aggressive NK cell leukemia is treated by chemotherapy, but response is typically poor.

Evolution Although extranodal NK/T cell lymphoma is usually localized at presentation, systemic progression often occurs, usually early in the course of disease. Common distant sites of involvement are the skin, liver, lung, gastrointestinal tract, testis, and rarely bone marrow. Patients with aggressive NK cell leukemia typically exhibits a rapidly progressive clinical course, with multi-organ failure and bleeding tendency.

Prognosis Clinical factors reported to have prognostic significance in extranodal NK/T cell lymphoma include stage and hulk of disease, B symptoms, age, performance status and International Prognostic Index. The overall survival for patients with extranodal NK/T cell lymphoma is 30-40%. Practically all patients with aggressive NK cell leukemia die from the disease within a few weeks or months of presentation.

Genetics

In contrast to T cells, NK cells do not show rearrangements of the TCR genes. As expected from their proposed normal counterpart, NK cell neoplasms show a germline configuration of the TCR genes and do not express TCR proteins on the cell surface. The detection of single circularised episomal form of EBV in the neoplasm by Southern blot analysis provides indirect evidence to the clonal nature. Molecular demonstration of X chromosome inactivation in female patients with NK cell neoplasms also provides evidence for clonality. However, the most direct evidence for clonallity of this group of tumors has been provided by the detection of clonal chromosomal abnormalities (see section below).
It has been shown that in over 90% of NK cell neoplasms, a specific pattern of promoter CpG methylation occurs, with p73 being consistently involved. It has been further suggested that p73 may be an important target in the oncogenesis of NK cell neoplasms, and the demonstration of its methylation may serve as a useful molecular marker for disease monitoring.

Cytogenetics

Note A variety of genetic abnormalities has been described, but so far no specific and consistent chromosomal translocation has been identified by conventional cytogenetics. In most instances, the genetic changes involve loss or gain of genetic materials such as del(6q), and i(1q). Frequent genetic losses in 6q and 13q have been confirmed by both comparative genomic hybridization (CGH) and loss of heterozygosity (LOH) analyses. Other non-random abnormalities include +X, i(1q), i(7q), +8, i(17q), and 11q23 rearrangement. Chromosomal deletion involving chromosome 6q at around q21-q25 is the commonest recurrent chromosomal abnormality, and fluorescence in situ hybridisation studies have shown that 6q22-q23 is the most frequently involved regions in the chromosome 6 deletions. A recent study using LOH and homozygoisty mapping of deletion (HOMOD) analyses has, however, defined a distinct 3 Mb smallest region of overlapping on 6q25.
A possible involvement of 8p22-p23 in both NK cell neoplasms and NK cell line such as NK-92 has also been suggested. Translocation involving 8p23 has been reported in 3 cases of NK cell neoplasms, with the partner chromosomes being 8q13, 17q24 and 1q10. An add(8)(q23) abnormality has also been demonstrated in one case each of aggressive NK cell leukemia and extranodal NK/T cell lymphoma.

Bibliography

Neural cell adhesion molecule-positive peripheral T-cell lymphoma: a rare variant with a propensity for unusual sites of involvement.

Kern WF, Spier CM, Hanneman EH, Miller TP, Matzner M, Grogan TM

Blood. 1992 ; 79 (9) : 2432-2437.

PMID 1373974

CD56 (NKH1)-positive hematolymphoid malignancies: an aggressive neoplasm featuring frequent cutaneous/mucosal involvement, cytoplasmic azurophilic granules, and angiocentricity.

Wong KF, Chan JK, Ng CS, Lee KC, Tsang WY, Cheung MM

Human pathology. 1992 ; 23 (7) : 798-804.

PMID 1377163

Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm.

Chan JK, Sin VC, Wong KF, Ng CS, Tsang WY, Chan CH, Cheung MM, Lau WH

Blood. 1997 ; 89 (12) : 4501-4513.

PMID 9192774

CD56+ NK lymphomas: clinicopathological features and prognosis.

Kwong YL, Chan AC, Liang R, Chiang AK, Chim CS, Chan TK, Todd D, Ho FC

British journal of haematology. 1997 ; 97 (4) : 821-829.

PMID 9217183

Identification of del(6)(q21q25) as a recurring chromosomal abnormality in putative NK cell lymphoma/leukaemia.

Wong KF, Chan JK, Kwong YL

British journal of haematology. 1997 ; 98 (4) : 922-926.

PMID 9326190

Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients.

Cheung MM, Chan JK, Lau WH, Foo W, Chan PT, Ng CS, Ngan RK

Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 ; 16 (1) : 70-77.

PMID 9440725

Comparative genomic hybridization analysis of natural killer cell lymphoma/leukemia. Recognition of consistent patterns of genetic alterations.

Siu LL, Wong KF, Chan JK, Kwong YL

The American journal of pathology. 1999 ; 155 (5) : 1419-1425.

PMID 10550295

Cytogenetic abnormalities in natural killer cell lymphoma/leukaemia--is there a consistent pattern?

Wong KF, Zhang YM, Chan JK

Leukemia & lymphoma. 1999 ; 34 (3-4) : 241-250.

PMID 10439361

Chromosome aberrations are restricted to the CD56+, CD3- tumour cell population in natural killer cell lymphomas: a combined immunophenotyping and FISH study.

Zhang Y, Wong KF, Siebert R, Matthiesen P, Harder S, Eimermacher H, Feller AC, Schlegelberger B

British journal of haematology. 1999 ; 105 (3) : 737-742.

PMID 10354139

Consistent patterns of allelic loss in natural killer cell lymphoma.

Siu LL, Chan V, Chan JK, Wong KF, Liang R, Kwong YL

The American journal of pathology. 2000 ; 157 (6) : 1803-1809.

PMID 11106552

Consistent patterns of allelic loss in natural killer cell lymphoma.

Siu LL, Chan V, Chan JK, Wong KF, Liang R, Kwong YL

The American journal of pathology. 2000 ; 157 (6) : 1803-1809.

PMID 11106552

Consistent patterns of allelic loss in natural killer cell lymphoma.

Siu LL, Chan V, Chan JK, Wong KF, Liang R, Kwong YL

The American journal of pathology. 2000 ; 157 (6) : 1803-1809.

PMID 11106552

Bone marrow involvement by nasal NK cell lymphoma at diagnosis is uncommon.

Wong KF, Chan JK, Cheung MM, So JC

American journal of clinical pathology. 2001 ; 115 (2) : 266-270.

PMID 11211616

Specific patterns of gene methylation in natural killer cell lymphomas : p73 is consistently involved.

Siu LL, Chan JK, Wong KF, Kwong YL

The American journal of pathology. 2002 ; 160 (1) : 59-66.

PMID 11786399

Genetic changes in natural killer cell neoplasms.

Wong KF

Leukemia research. 2002 ; 26 (11) : 977-978.

PMID 12363463

Natural killer cell neoplasms: a distinctive group of highly aggressive lymphomas/leukemias.

Cheung MM, Chan JK, Wong KF

Seminars in hematology. 2003 ; 40 (3) : 221-232.

PMID 12876671

Aberrant promoter CpG methylation as a molecular marker for disease monitoring in natural killer cell lymphomas.

Siu LL, Chan JK, Wong KF, Choy C, Kwong YL

British journal of haematology. 2003 ; 122 (1) : 70-77.

PMID 12823347

A 2.6 Mb interval on chromosome 6q25.2-q25.3 is commonly deleted in human nasal natural killer/T-cell lymphoma.

Sun HS, Su IJ, Lin YC, Chen JS, Fang SY

British journal of haematology. 2003 ; 122 (4) : 590-599.

PMID 12899714

Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index.

Chim CS, Ma SY, Au WY, Choy C, Lie AK, Liang R, Yau CC, Kwong YL

Blood. 2004 ; 103 (1) : 216-221.

PMID 12933580

A novel EBV-negative natural killer cell line.

Wong KF

Leukemia research. 2004 ; 28 (3) : 225-227.

PMID 14687616

Contributor(s)

Written 04-2004 K.F. Wong

Department of Pathology, Queen Elizabeth Hospital, 30 Gascoigne Road, Kowloon, Hong Kong SAR, China

Citation

This paper should be referenced as such :
Wong KF . NK cell neoplasias. Atlas Genet Cytogenet Oncol Haematol. April 2004 .
URL : http://AtlasGeneticsOncology.org/Anomalies/NKCellNeoplasiaID2125.html

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Mon May 12 18:11:23 2008

Home Genes Leukemias Solid Tumours Cancer-Prone Deep Insight Case Reports Journals Portal Teaching

For comments and suggestions or contributions, please contact us

j.l.huret@chu-poitiers.fr.

Disease	Neoplasms of natural killer (NK) cells are rare, and have not been well characterized until the past decade. In the new WHO classification of hematolymphoid tumors, three categories of NK cell neoplasms are recognized: - extranodal NK/T cell lymphoma , - aggressive NK cell leukemia, and - blastic NK cell lymphoma. Blastic NK cell lymphoma is morphologically and immunologically different from the first two categories, lacks EBV association, and there is little compelling evidence that it truly represents an NK cell neoplasm. In fact, recent studies suggest that this may be a neoplasm of probable precursor dendritic cells related to plasmacytoid monocytes (plasmacytoid dendritic cells). Since its lineage is still uncertain, this entity will not be discussed.
Phenotype / cell stem origin	NK cell represents a distinctive lineage of lymphocyte that is closely related to T cell. It shows many immunophenotypic and functional similarities with cytotoxic T lymphocyte, but differs in the lack of expression of surface CD3 molecule and T-cell receptor, and the absence of rearranged T-cell receptor genes. It characteristically expresses CD56 (neuronal cell adhesion molecule, N-CAM), which is also expressed in some cytotoxic T lymphocytes. NK cells can lyse target cells without prior sensitization (spontaneous antibody-independent MHC-unrestricted cytotoxicity) via the NK receptors.
Etiology	The exact etiology is unknown, but a very strong association with Epstein Barr virus (EBV) has been demonstrated.
Epidemiology	NK cell neoplasms show a strong geographic differences in their prevalence. They are more common in Asia, Mexico, and South America, but are very rare in the Western populations.
Clinics	They occur predominantly in the nose/nasopharynx, but sometimes in extranasal sites (most commonly skin), in middle-aged to elderly patients. Systemic involvement is uncommon at diagnosis but rarely, they may present initially in a leukemic form. The most common presenting symptoms are nasal obstruction, nasal discharge and epistaxis. The full-blown midfacial destructive and ulcerative lesions (hence the name midline granuloma) are much less commonly seen nowadays. Patients with aggressive NK cell leukemia present with high swinging fever, systemic symptoms and hepatosplenomegaly; they are usually extremely ill, with deranged liver function and coagulation profile.
Cytology	The neoplastic NK cells are often heterogeneous in appearance but some (particularly the circulating leukemic cells) may resemble large-sized normal large granular lymphocytes with ample amount of pale or lightly blue cytoplasm that contains fine or coarse azurophilic granules.
Pathology	The malignant infiltrate is diffuse, often with a prominent angiocentric and angiodestructive component. Coagulative necrosis and apoptosis are common. The cytological spectrum is variable, ranging from small, medium-sized, large or anaplastic cells, to a mixture of these cells. The cells often have irregularly folded nuclei and granular chromatin. In Giemsa-stained cytologic preparations, azurophilic granules are often detected in the cytoplasm. Reactive histiocytes with haemophagocytosis are sometimes found in the bone marrow, particularly for the leukemic form. NK cell neoplasms are characterised by an immunophenotype of CD2+, surface CD3-, cytoplasmic CD3e+, CD56+ and T cell receptor (TCR)-, lack of TCR gene rearrangement, and strong association with EBV.
Treatment	The disease is often resistant to chemotherapy. For extranodal NK/T cell lymphoma, the best results are obtained by radiotherapy with or without aggressive chemotherapy/stem cell rescue. Plasma or serum EBV DNA and tissue p73 gene hypermethylation assay can be used for monitoring of disease status or detection of minimal residual disease. Aggressive NK cell leukemia is treated by chemotherapy, but response is typically poor.
Evolution	Although extranodal NK/T cell lymphoma is usually localized at presentation, systemic progression often occurs, usually early in the course of disease. Common distant sites of involvement are the skin, liver, lung, gastrointestinal tract, testis, and rarely bone marrow. Patients with aggressive NK cell leukemia typically exhibits a rapidly progressive clinical course, with multi-organ failure and bleeding tendency.
Prognosis	Clinical factors reported to have prognostic significance in extranodal NK/T cell lymphoma include stage and hulk of disease, B symptoms, age, performance status and International Prognostic Index. The overall survival for patients with extranodal NK/T cell lymphoma is 30-40%. Practically all patients with aggressive NK cell leukemia die from the disease within a few weeks or months of presentation.

Written	04-2004	K.F. Wong
		Department of Pathology, Queen Elizabeth Hospital, 30 Gascoigne Road, Kowloon, Hong Kong SAR, China